# | Title | Journal | Year | Citations |
---|
1 | Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients | Nature | 2014 | 4,342 |
2 | Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib | New England Journal of Medicine | 2012 | 1,955 |
3 | Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial | Lancet Oncology, The | 2019 | 1,467 |
4 | Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial | Lancet Oncology, The | 2015 | 1,419 |
5 | Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs | JAMA - Journal of the American Medical Association | 2014 | 1,386 |
6 | Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial | Lancet Oncology, The | 2015 | 1,269 |
7 | Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer | Nature Genetics | 2012 | 1,186 |
8 | Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial | Lancet Oncology, The | 2016 | 1,091 |
9 | Transforming Growth Factor-β1 Mediates Epithelial to Mesenchymal Transdifferentiation through a RhoA-dependent Mechanism | Molecular Biology of the Cell | 2001 | 962 |
10 | Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study | Journal of Clinical Oncology | 2019 | 811 |
11 | TGF-β and immune cells: an important regulatory axis in the tumor microenvironment and progression | Trends in Immunology | 2010 | 805 |
12 | Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer | Science Translational Medicine | 2010 | 761 |
13 | Acquired resistance to TKIs in solid tumours: learning from lung cancer | Nature Reviews Clinical Oncology | 2014 | 740 |
14 | Superiority of Oxaliplatin and Fluorouracil-Leucovorin Compared With Either Therapy Alone in Patients With Progressive Colorectal Cancer After Irinotecan and Fluorouracil-Leucovorin: Interim Results of a Phase III Trial | Journal of Clinical Oncology | 2003 | 613 |
15 | Subsequent Neoplasms in 5-Year Survivors of Childhood Cancer: The Childhood Cancer Survivor Study | Journal of the National Cancer Institute | 2010 | 598 |
16 | Proteomic patterns of tumour subsets in non-small-cell lung cancer | Lancet, The | 2003 | 597 |
17 | Experimentally Derived Metastasis Gene Expression Profile Predicts Recurrence and Death in Patients With Colon Cancer | Gastroenterology | 2010 | 576 |
18 | HER kinase inhibition in patients with HER2- and HER3-mutant cancers | Nature | 2018 | 572 |
19 | Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance | Nature Communications | 2012 | 567 |
20 | Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial | Lancet, The | 2016 | 529 |
21 | A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group | Oncologist | 2020 | 520 |
22 | Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance | Cell | 2015 | 516 |
23 | COX-2: A Molecular Target for Colorectal Cancer Prevention | Journal of Clinical Oncology | 2005 | 497 |
24 | Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study | Journal of Clinical Oncology | 2019 | 494 |
25 | Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium | Journal of Clinical Oncology | 2020 | 481 |
26 | Interdependent SMAD and JNK Signaling in Transforming Growth Factor-β-mediated Transcription | Journal of Biological Chemistry | 1999 | 476 |
27 | First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers | Journal of Clinical Oncology | 2019 | 457 |
28 | Mortality Associated With Irinotecan Plus Bolus Fluorouracil/Leucovorin: Summary Findings of an Independent Panel | Journal of Clinical Oncology | 2001 | 414 |
29 | Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy | Nature Nanotechnology | 2019 | 406 |
30 | Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study | Lancet Oncology, The | 2017 | 402 |
31 | Cyclooxygenase-2 and Epidermal Growth Factor Receptor: Pharmacologic Targets for Chemoprevention | Journal of Clinical Oncology | 2005 | 379 |
32 | Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience | Journal of Thoracic Oncology | 2015 | 357 |
33 | Integrin β1 Signaling Is Necessary for Transforming Growth Factor-β Activation of p38MAPK and Epithelial Plasticity | Journal of Biological Chemistry | 2001 | 354 |
34 | Ibrutinib for chronic graft-versus-host disease after failure of prior therapy | Blood | 2017 | 352 |
35 | The Epidemiology of Renal Cell Carcinoma | Journal of Urology | 2006 | 349 |
36 | Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma | Journal of Clinical Oncology | 2013 | 335 |
37 | Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study | Lancet Oncology, The | 2017 | 322 |
38 | The landscape of recombination in African Americans | Nature | 2011 | 319 |
39 | KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study | Lancet, The | 2021 | 315 |
40 | Prostaglandin E2 promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor δ | Cancer Cell | 2004 | 314 |
41 | EML4-ALK: Honing In on a New Target in Non–Small-Cell Lung Cancer | Journal of Clinical Oncology | 2009 | 313 |
42 | Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma | American Journal of Hematology | 2019 | 305 |
43 | Treatment of Metastatic Renal Cell Carcinoma With a Combination of Bevacizumab and Erlotinib | Journal of Clinical Oncology | 2005 | 298 |
44 | Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial | Lancet Oncology, The | 2016 | 293 |
45 | First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study | Journal of Clinical Oncology | 2022 | 283 |
46 | Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer | Cancer Research | 2005 | 283 |
47 | Myocarditis in the Setting of Cancer Therapeutics | Circulation | 2019 | 278 |
48 | Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families | Journal of Clinical Oncology | 2020 | 270 |
49 | Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer | Proceedings of the National Academy of Sciences of the United States of America | 2009 | 251 |
50 | A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia | Cancer Discovery | 2018 | 250 |